Self-administration of Recombinant Human Growth Hormone with an Electronic Device: Clinical, Economic and Management Benefits of Objective Adherence Monitoring
Open Access
- 1 January 2013
- journal article
- Published by The Journal of Health Economics and Outcomes Research in Journal of Health Economics and Outcomes Research
- Vol. 1 (3) , 296-307
Abstract
Purpose: The aim was to identify factors affecting treatment adherence and to assess the clinical, economic and management impact of growth hormone deficiency treatment using an electronic auto-injector for recombinant human growth hormone (r-hGH) administration in children. Patients and Methods: A literature review was conducted in PubMed up to 31JUL2013, including the following search terms: “growth hormone deficiency”, “human-recombinant growth hormone” and “treatment adherence”. An economic model was developed to estimate the economic benefits of using an electronic injection device. In order to quantify this benefit, potential savings due to growth hormone cartridge optimization were analyzed. Results: From the literature review, the following key factors were found to affect treatment adherence: type of device used, discomfort, complexity of treatment regimens, long-term treatment, age and patient or family understanding of treatment benefits were assessed. A better adjustment to prescribed daily dose (accuracy up to 0.01 mg) with the electronic device results in a better optimization of vials and could save an average of 5% of total treatment costs in terms of doses not wasted, amounting to €245 of potential savings per patient and year of treatment. Conclusion: The use of an electronic device for r-hGH administration and monitoring may provide a better identification of responder and adherent patients. It may also generate savings in annual r-hGH consumption by hospitals and regional healthcare services.Keywords
This publication has 32 references indexed in Scilit:
- Identification and management of poor response to growth‐promoting therapy in children with short statureClinical Endocrinology, 2012
- Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: A noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patientsClinical Therapeutics, 2010
- Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: An open-label, uncontrolled usability testClinical Therapeutics, 2009
- Observations of nonadherence to recombinant human growth hormone therapy in clinical practiceClinical Therapeutics, 2008
- Monitoring of concordance in growth hormone therapyArchives of Disease in Childhood, 2007
- Facilitating and understanding the family’s choice of injection device for growth hormone therapy by using conjoint analysisArchives of Disease in Childhood, 2007
- Current prescribing practices and opinions about growth hormone therapy: results of a nationwide survey of paediatric endocrinologistsClinical Endocrinology, 2006
- Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatmentThe Lancet, 2004
- Update of guidelines for the use of growth hormone in children: the Lawson Wilkins pediatric endocrinology society drug and therapeutics committeeThe Journal of Pediatrics, 2003
- Multicentre survey on compliance with growth hormone therapy: what can be improved?Acta Paediatrica, 1998